VOR BIOPHARMA INC (VOR)
Health Care · Clinical-stage biopharmaceutical (cell and gene therapy) · NASDAQ
Vor Biopharma is a clinical-stage biopharmaceutical company developing advanced cell therapy and gene therapy solutions for blood disorders and cancers.
What VOR BIOPHARMA INC does
Vor Biopharma is a clinical-stage cell therapy company focused on developing engineered hematopoietic stem cell (HSC) transplants to improve the safety and efficacy of cancer treatments. The company’s platform designs engineered HSCs that can be used in combination with targeted therapies to selectively eliminate cancer cells while sparing healthy, engineered blood cells. Its lead programs are designed to address limitations in current stem cell transplantation and targeted therapy treatments for hematological malignancies.
Themes: cell therapy, gene therapy, blood disorders, oncology, hematologic malignancies, clinical-stage development
Fundamentals
- Price$23.36 as of 2026-08-21 close
- Market cap$1.4B as of 2026-08-21
- 1-year return-46.2% 2025-08-21 close $43.40 → 2026-08-21 close $23.36
- P/En/a earnings data not available
- ROE-142.1% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Beta1.64 as of 2026-08-24
- Last reported earnings2026-01-12 most recent in our data — SEC EDGAR Form 8-K (Item 2.02); no newer announcement filed
How VOR compares in its sector
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How VOR BIOPHARMA INC looks technically
VOR BIOPHARMA INC (VOR) is trading 51.2% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 20 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 34, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 62, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 5 trading days ago (its momentum flipped negative). It made a new 20-day high about 12 trading days ago. It is 53.5% below its highest point of the past year.
Trend
9
| Distance from the 200-day | it is trading 51.2% above its 200-day average, the long-term trend line — a longer-term uptrend | +51.2% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $19.39 | $19.39 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $15.45 | $15.45 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 9 calendar days ago — the swings before that are what the structure reading is measured on | 9 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 21.75. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 20 trading days ago — a "golden cross", a bullish long-term signal | 20 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 51.2% above | +51.2% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 34, with buyers in control | 34.2 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 62, neither overbought (above 70) nor oversold (below 30) | 62.1 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($21.51 to $24.54) — its "stochastic" reading is 61 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 61.1 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 5 trading days ago (its momentum flipped negative) | 5 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $50.20 | $50.20 |
|---|---|---|
| From the 52-week high | it is 53.5% below its 52-week high (its highest price of the past year) | -53.5% |
| Above the 52-week low | it is 259.4% above its 52-week low (its lowest price of the past year) | +259.4% |
| Below the 52-week high | it is 53.5% below its highest point of the past year | 53.5% |
| Since a 20-day breakout | it made a new 20-day high about 12 trading days ago | 12 sessions |
| Since a 55-day breakout | it made a new 55-day high about 12 trading days ago | 12 sessions |
| All-time high | its highest closing price on record is $1272.40 (set on 2021-02-05) | $1272.40 |
| Given back of the 52-week move | over the past year its closes ranged ($6.86 to $48.72), and it has recovered roughly a third of its fall from last year’s high — 39% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $32.73 to $34.07. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 39.4% |
| From the all-time high | it is 98.2% below its all-time high | -98.2% |
| Nearest price level | it is trading 4.3% below a resistance level at $24.37 — a price it turned at twice since 2025-01-23, most recently on 2026-08-07. Since 2024-08-21 it has 7 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +4.3% |
| All-time low | its lowest closing price on record is $2.62 (set on 2025-05-09) | $2.62 |
| Above the all-time low | it is 791.6% above its all-time low | +791.6% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 83% of it) | 17th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.29 between its high and its low — about 5.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.29 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $19.66 and $25.05 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $19.66 – $22.36 – $25.05 |
| Typical daily range (% of price) | its price moves about 5.5% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.5% |
| Stretch from the 200-day average | it is trading 6.2 daily ranges above its 200-day average price (51.2% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 6.2 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.70× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 3.0% since the prior reading | +3.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
2
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|---|---|
| Since a hammer | 5 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 5 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 2.2% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +2.2% |
|---|---|---|
| Open gap | it gapped 2.2% above the previous close today and has not traded back through the level it left behind at 23.07 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.2% |
| Gap filled | a 2.3% gap down opened on 2026-08-20 has been "filled" today — price traded back through the level the gap left behind, and it took 1 session to close | today |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 14.2 percentage points (the stock gained 16.5% while the market gained 2.3%) | +14.2% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 52.2 percentage points (the stock gained 55.3% while the market gained 3.1%) | +52.2% |
| vs market, 6 months | over the past 6 months this stock beat the market by 61.3 percentage points (the stock gained 72.4% while the market gained 11.1%) | +61.3% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 66.7 percentage points (the stock lost 46.2% while the market gained 20.5%) | -66.7% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: MACD momentum is negative — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 28% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 3.3% of the share price. | +27.7% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 44% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $16.23 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | +43.9% |
|---|
Price levels it has turned at before
VOR last closed at $23.36 on 2026-08-21. Since 2024-08-21 it has turned at 7 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $24.37 | Resistance | 4.3% above the last close | turned there twice · 2025-01-23 to 2026-08-07 |
| $21.88 | Support | 6.4% below the last close | turned there twice · 2024-12-09 to 2026-08-12 |
| $18.26 | Support | 21.8% below the last close | turned there twice · 2024-10-31 to 2026-05-11 |
| $16.81 | Support | 28.0% below the last close | turned there five times · 2025-04-23 to 2026-07-17 |
| $31.60 | Resistance | 35.3% above the last close | turned there twice · 2025-01-24 to 2025-02-06 |
| $50.08 | Resistance | 114.4% above the last close | turned there twice · 2025-08-25 to 2025-09-30 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $21.75.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $29.42 and $34.16 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $21.75.
This reading has stood for 3 trading days, since 2026-08-19.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Tested and reclaimed 200-day support · Pulled back from the 12-month high · MACD just crossed bearish (12/26/9) · in a strong, established uptrend (ADX) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.33 mean, 1=Strong Buy…5=Strong Sell) — 8 analysts
- Mean price target$39.00 range $27.00 – $50.00; median $40.00
Analyst estimates, as of 2026-08-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for VOR
- Consensus EPS estimate-$0.703 next reporting period, as of 2026-08-18
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on ability to successfully advance product candidates through clinical trials and obtain regulatory approval; clinical development involves substantial risks and uncertainties","Significant capital requirements to fund ongoing research, development, and potential commercialization efforts; need for additional funding with uncertain availability","Reliance on intellectual property licensed from third parties and ability to maintain such licenses on commercially reasonable terms"]
What changed in the latest 10-Q
AI-assisted comparison of VOR's 10-Q filed 2026-05-13 against the prior one filed 2025-11-13.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to 2025 Annual Report instead of 2024 Annual Report (newer filing dated 2026-05-13)
- Statement that telitacicept has two BLAs 'filed and pending' in China for SjD and IgAN (newer filing)
- Statement that topline data from gMG Phase 3 trial is anticipated in first half of 2027 (newer filing)
- Reference to 48-week data from Part B of Phase 3 gMG trial presented at AANEM Annual Meeting in October 2025 (newer filing)
- New paragraph describing Phase 3 clinical trial for SjD with first patient dosed in March 2026 and expected recruitment of approximately 250 adults (newer filing)
- Reference to 48-week data including Stage A and B from Phase 3 SjD trial presented at ACR Annual Meeting in October 2025 (newer filing)
- Net loss of $219.6 million for three months ended March 31, 2026 and $32.5 million for three months ended March 31, 2025 (newer filing)
- Accumulated deficit of $1,372.6 million as of March 31, 2026 (newer filing)
- Cash, cash equivalents and marketable securities of $491.5 million as of March 31, 2026 (newer filing)
- Statement that cash is expected to fund operations into early 2029 (newer filing)
- Section on Critical Accounting Estimates with statement that there have been no changes from 2025 Annual Report (newer filing)
- Removed:
- Detailed description of telitacicept mechanism of action (TACI receptor, Fc domain, BLyS/BAFF, APRIL targeting) present in older filing removed from newer filing
- Statement that RemeGen 'has also filed' BLAs in China (older filing language) replaced with 'has two BLAs filed and pending' (newer filing)
- Detailed gMG Phase 3 trial results data (MG-ADL and QMG mean changes, percentage improvements, safety profile details) present in older filing not included in newer filing
- Reference to 'broader development plan' and exploration of additional autoantibody-driven diseases (older filing) removed from newer filing
- Detailed SjD Phase 3 trial results data (ESSDAI scores, ESSPRI scores, MFI-20 fatigue data, percentages at various timepoints) present in older filing not included in newer filing
- Restructuring Plan section describing May 5, 2025 board approval, wind down of existing operations, workforce reduction of 154 employees and restructuring costs of $29.7 million (older filing) removed from newer filing
- Net loss of $812.7 million for three months ended September 30, 2025, $2,418.8 million for nine months ended September 30, 2025, and $116.9 million for year ended December 31, 2024 (older filing) replaced with different figures for different periods (newer filing)
- Accumulated deficit of $2,875.8 million as of September 30, 2025 (older filing) replaced with $1,372.6 million as of March 31, 2026 (newer filing)
- Cash balance of $170.5 million as of September 30, 2025 and reference to net proceeds of $49.8 million (older filing) replaced with $491.5 million as of March 31, 2026 (newer filing)
- Reworded:
- Changed from 'are assuming responsibility' to 'have assumed responsibility' for gMG Phase 3 trial (past tense in newer filing)
- Removed reference to 'open-label treatment period (Part B)' and replaced with 'Part B' in gMG trial data description (newer filing)
- Changed 'Sjögren's disease' abbreviation from 'SD' (older filing) to 'SjD' (newer filing)
- Removed sentence about 'no approved disease-modifying systemic therapies for Sjögren's disease' (older filing statement not in newer filing)
- Notes:
- The newer filing (2026-05-13) covers the period ended March 31, 2026, while the older filing (2025-11-13) covers the period ended September 30, 2025, making direct financial comparison between different quarters
- The section appears truncated in the newer filing text (ends mid-sentence: 'A significant portion of our research and development costs have be'), limiting complete assessment of all changes in that section
- The older filing appears to be incomplete or truncated (ends mid-sentence regarding net proceeds), affecting full comparison of certain sections
Risk Factors
- Added:
- In the newer filing (2026-05-13), the forward-looking statements bullet point was revised to remove reference to 'preclinical and clinical trials for any future product candidates' and now reads only 'clinical trials of our product candidate and any future product candidates'
- Removed:
- Removed reference to 'preclinical and clinical trials' in the context of future product candidates in the forward-looking statements section (older filing 2025-11-13)
- Reworded:
- The reference to the Annual Report on Form 10-K year changed from 'December 31, 2024' in the older filing to 'December 31, 2025' in the newer filing
- Item page number for Risk Factors changed from page 26 (older filing 2025-11-13) to page 22 (newer filing 2026-05-13)
- Item page number for Other Information changed from page 67 (older filing 2025-11-13) to page 64 (newer filing 2026-05-13)
- Item page number for Signatures changed from page 70 (older filing 2025-11-13) to page 68 (newer filing 2026-05-13)
- Notes:
- The newer filing text appears truncated at 'We face significant competition in an environment of rapid technological' while the older filing is similarly truncated at 'We face significant competition in an', preventing full comparison of this section
- Only the introductory and summary risk factors portions were provided; the detailed Risk Factors section was not included in either filing text
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 1 open-market sale by insiders in the last 90 days.
- Last 90 days0 buys · 1 sell ($4207) — 1 selling insider
- Last 180 days0 buys · 16 sells ($49M) — 1 selling insider
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-16. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about VOR's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding VOR as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 3,730,494
- Reported value $66,552,014
reported quarterly holdings change (2025-12-31 → 2026-03-31): 1 new, 2 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
VOR had 7,251,707 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
VOR had 12.3% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 8.32 days to cover at the same settlement.
- Reported short interest (shares) 7,251,707
- Short interest (% of shares outstanding) 12.3%
- Prior settlement (shares) 7,289,116
- Reported change -0.51%
- Days to cover (reported) 8.32
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Gilead Sciences (Kite Pharma) (GILD)
- Novartis (NVS)
- Bristol Myers Squibb (BMY)
- Legend Biotech (LEGN)
- Autolus Therapeutics (AUTL)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare VOR vs…
VOR BIOPHARMA INC is found in…
Frequently asked questions
What does VOR BIOPHARMA INC (VOR) do?
Vor Biopharma is a clinical-stage cell therapy company focused on developing engineered hematopoietic stem cell (HSC) transplants to improve the safety and efficacy of cancer treatments. The company’s platform designs engineered HSCs that can be used in combination with targeted therapies to selectively eliminate cancer cells while sparing healthy, engineered blood cells.
What sector is VOR BIOPHARMA INC (VOR) in?
VOR BIOPHARMA INC (VOR) is classified in the Health Care sector. Its industry is Clinical-stage biopharmaceutical (cell and gene therapy). It trades on NASDAQ.
Who are VOR BIOPHARMA INC's (VOR) competitors?
Notable peers of VOR BIOPHARMA INC (VOR) include Gilead Sciences (Kite Pharma), Novartis, Bristol Myers Squibb, Legend Biotech and Autolus Therapeutics. This peer set is informational only — not financial advice.
Is VOR BIOPHARMA INC (VOR) overbought or oversold right now?
VOR BIOPHARMA INC (VOR) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 62, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on VOR come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.